REDHILL BIOPHARMA LTD-SP ADR (RDHL)
US7574682024 - ADR
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
RedHill continues corporate transformation to focus on U.S. government-funded pipeline development in underserved, sizeable therapeutic areas with a...
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered...
RedHill Announces New USPTO Patent Covering Talicia® Through 2034
U.S. Patent and Trademark Office (USPTO) issues new patent covering Talicia1 as an all-in-one treatment of Helicobacter pylori (H. pylori), supporting Talicia...
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
The U.S. government's Chemical Medical Countermeasures (Chem MCM) Program and Chemical Countermeasures Research Program (CCRP), managed respectively by...
RedHill Biopharma files to sell 10.6M ADS for holders (NASDAQ:RDHL)
Read about RedHill Biopharma's filing of a prospectus for the resale of 10.6M ADSs, representing 400 shares each, by selling stockholders.
RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering
/PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has closed...
RedHill Biopharma Announces $8 Million Registered Direct Offering
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered...
RedHill gains on patent grant for Talicia for H. pylori treatment (NASDAQ:RDHL)
RedHill Biopharma's new patent for Talicia, a method for eradicating H.
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042
USPTO issues new patent covering Talicia[1] as a method for eradicating H. pylori regardless of patient Body Mass Index (BMI)[2], supporting Talicia protection...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers on Tuesday with a breakdown of all the latest news affecting shares this morning.
Gilead’s Quiet Revolution: Is GILD the Next Big Stock to Soar?
While Wall Street obsesses over weight-loss drugs, Gilead Sciences is working on life-saving treatments and GILD stock looks ready to rally.
RedHill shares rally 20% on positive data for two antiviral drugs (NASDAQ:RDHL)
RedHill Biopharma (RDHL) shares soared 20% on positive results from a laboratory study of its drugs opaganib and RHB-107 in combination with remdesivir. Read more here.
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
Investigational drugs opaganib and RHB-107 (upamostat) demonstrate distinct synergistic effect when combined individually with remdesivir, significantly...
RedHill Biopharma regains compliance with Nasdaq listing rule (NASDAQ:RDHL)
RedHill Biopharma regains compliance with Nasdaq's minimum bid price requirement after trading above $1.00 for 10 consecutive days.
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it received...
RedHill secures funding for Phase 2 study of COVID-19 treatment (NASDAQ:RDHL)
Israeli company RedHill (RDHL) has received $4.8M in non-dilutive funding for a Phase 2 study of its oral antiviral drug RHB-107 in the treatment of early COVID-19. Read more here.
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
The new non-dilutive external funding, additional to the previously announced U.S. Government non-dilutive funding, now covers the entirety of the RHB-107...
Why Is ImmunoGen (IMGN) Stock Up 81% Today?
ImmunoGen stock is taking off on news that AbbVie is acquiring all outstanding shares of IMGN in a $10.1 billion acquisition deal.
Why Is Redhill Biopharma (RDHL) Stock Down 27% Today?
Redhill Biopharma stock is falling on Thursday as shares of RDHL give up some of the gains they made throughout the week.